- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05079217
Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19
13. februar 2022 opdateret af: Sinovac Biotech Co., Ltd
A Randomized, Double-Blinded Clinical Trial to Evaluate Additional Dose of Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine in Healthy Individuals Previously Vaccinated With CoronaVac
This is a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine manufactured by manufactured by Sinovac Research & Development Co., Ltd.
The purpose of this study is to evaluate the safety and immunogenicity of booster vaccination with high-dosage SARS-CoV-2 vaccine in populations who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month.
Studieoversigt
Status
Aktiv, ikke rekrutterende
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study a randomized, double-blinded, phase ⅠV clinical trial of SARS-CoV-2 inactivated vaccine .The purpose of this study is to evaluate the safety and immunogenicity of booster vaccination with high-dosage SARS-CoV-2 vaccine in populations who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month.A total of 1200 subjects who have received two-dose Coronavac with 2nd dose vaccinated more than 6 month will be enrolled.All of subjects will be randomly divided into two groups in a 1:1 ratio .Subjects in experimental group will receive high-dosage SARS-CoV-2 inactivated vaccine.Subjects in control group will receive medium-dosage SARS-CoV-2 inactivated vaccine .
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
1200
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Jiangsu
-
Xinqi, Jiangsu, Kina, 221400
- Xinqi City Center for Disease Control and Prevention
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Adults aged 18-59;
- Proven legal identity;
- The subjects can understand and voluntarily sign the informed consent form and be willing to complete the study in accordance with the study plan;
- Have received two doses of inactivated SARS-CoV-2 vaccine(CoronaVac) manufactured by Sinovac Research & Development Co., Ltd at an interval of 21 to 35 days and is currently 6-8 months (180 to 240 days) after the second dose.
Exclusion Criteria:
- History of SARS-CoV-2 infection(laboratory confirmed);
- Have received three and more doses of inactivated SARS-CoV-2 vaccine;
- Severe adverse reactions, such as urticaria, dyspnea, and angioneurotic edema , occurred during the primary immunization;
- Autoimmune disease such as systemic lupus erythematosus or immunodeficiency / immunosuppression such as AIDS, post-transplant;
- Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc;
- Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
- Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
- Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
- History of alcohol or drug abuse;
- Receipt of blood products within in the past 3 months;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Acute diseases or acute exacerbation of chronic diseases within 7 days prior to booster vaccination;
- Axillary temperature >37.0°C;
- Already pregnant or are breastfeeding, planning to get pregnant within 1months (according to subjects' self-report and urine pregnancy test results);
- Participated in other clinical trials prior to enrollment and during the follow-up period, or planned to participate in other clinical trials during the clinical trial period;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Experimental Group
600 participants will receive one dose of booster vaccination with high-dosage inactivated SARS-CoV-2 vaccine .
|
SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Andre navne:
|
Aktiv komparator: Control Group
600 participants will receive one dose of booster vaccination with medium-dosage inactivated SARS-CoV-2 vaccine .
|
SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity index-GMT of neutralizing antibodies(CZ02 strain)
Tidsramme: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination.
|
Day 28 after booster vaccination
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity index-seropositive rate of neutralizing antibodies(CZ02 strain)
Tidsramme: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(CZ02 strain)
Tidsramme: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(CZ02 strain)
Tidsramme: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(CZ02 strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seropositive rate of neutralizing antibodies(Delta Strain)
Tidsramme: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(Delta Strain)
Tidsramme: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(Delta Strain)
Tidsramme: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seroconversion rate of neutralizing antibodies(Omicron Strain)
Tidsramme: Day 28 after booster vaccination
|
The seroconversion rate of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-seropositive rate of neutralizing antibodies(Omicron Strain)
Tidsramme: Day 28 after booster vaccination
|
The seropositive rate of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMI of neutralizing antibodies(Omicron Strain)
Tidsramme: Day 28 after booster vaccination
|
GMI of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(Omicron Strain)
Tidsramme: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(Omicron Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(Delta Strain)
Tidsramme: Day 28 after booster vaccination
|
GMT of neutralizing antibodies(Delta Strain) 28 days after booster vaccination
|
Day 28 after booster vaccination
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity index-the seropositive rate of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain)
Tidsramme: 6 months after the booster vaccination
|
The seroconversion rate of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain) 6 months after the booster vaccination
|
6 months after the booster vaccination
|
Immunogenicity index-GMT of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain)
Tidsramme: 6 months after the booster vaccination
|
GMI of neutralizing antibodies(CZ02 strain,Delta Strain and Omicron Strain) 6 months after the booster vaccination
|
6 months after the booster vaccination
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Hongxing Pan, Master, Jiangsu Provincial Center for Disease Prevention and Control
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
17. december 2021
Primær færdiggørelse (Faktiske)
21. december 2021
Studieafslutning (Forventet)
1. juni 2022
Datoer for studieregistrering
Først indsendt
14. oktober 2021
Først indsendt, der opfyldte QC-kriterier
14. oktober 2021
Først opslået (Faktiske)
15. oktober 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
2. marts 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. februar 2022
Sidst verificeret
1. oktober 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PRO-nCOV-4007
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med COVID-19
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftvejsinfektion | COVID-19 stresssyndrom | COVID-19-vaccinebivirkning | COVID-19-associeret tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-associeret slagtilfældeKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbejdspartnereAfsluttetPostakutte følgesygdomme af COVID-19 | Tilstand efter COVID-19 | Langtids-COVID | Kronisk COVID-19 syndromItalien
-
Massachusetts General HospitalRekrutteringPostakut COVID-19 syndrom | Lang COVID | Postakutte følgesygdomme af COVID-19 | Lang COVID-19Forenede Stater
-
Indonesia UniversityRekrutteringPost-COVID-19 syndrom | Lang COVID | Tilstand efter COVID-19 | Post-COVID syndrom | Lang COVID-19Indonesien
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutteringCovid-19-pandemi | Vacciner mod covid-19 | COVID-19 virus sygdomIndonesien
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital og andre samarbejdspartnereRekrutteringKohorteopfølgning af epidemi og neuroimaging for patienter under den første bølge af COVID-19 i KinaCOVID-19 | Post-COVID-19 syndrom | Post-akut COVID-19 | Akut COVID-19Kina
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkIkke rekrutterer endnuPost-COVID-19 syndrom | Lang COVID | Lang Covid19 | Tilstand efter COVID-19 | Post-COVID syndrom | Tilstand efter COVID-19, uspecificeret | Post-COVID tilstandHolland
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyAfsluttetPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutteringCOVID-19 lungebetændelse | COVID-19 luftvejsinfektion | Covid-19-pandemi | COVID-19 Akut Respiratorisk Distress Syndrome | COVID-19-associeret lungebetændelse | COVID 19 associeret koagulopati | COVID-19 (Coronavirus sygdom 2019) | COVID-19-associeret tromboembolismeGrækenland
Kliniske forsøg med High-dosage SARS-CoV-2 vaccine
-
Istituto Clinico HumanitasRekruttering
-
Kern Medical CenterAfsluttetCOVID-19 | Sociale determinanter for sundhed | Penetrerende skadeForenede Stater
-
Kern Medical CenterAfsluttetCOVID-19 | Postoperative komplikationer | Kirurgiske resultaterForenede Stater